




ATC codes: **L01CD01**

Indication	Malignant neoplasms of breast <span style="background-color: #008080; color: white; padding: 2px;">ICD11 code: 2D2Z</span>
INN	Paclitaxel
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 6 mg per mL
EML status history	First added in 2011 ( <a href="#">TRS 965</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Paclitaxel</a> 
DrugBank	<a href="#">Paclitaxel</a> 

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for paclitaxel on the complementary list of the EML for use in treatment protocols for early-stage breast cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for early-stage breast cancer is attached.

[Expert Committee report](#) 

